News Releases

Texas Oncology, one of the largest community-based oncology practices in the U.S., recently expanded its pediatric hematology-oncology services in East Texas to improve access to specialized cancer care. The new satellite office — located in Tyler on the campus of Northeast Texas Cancer and Research Institute — will extend care services for children and adolescents in the East Texas community as one of only two sites in the region offering specialized pediatric cancer and blood disorder services.

Texas Oncology, one of the largest community-based oncology practices in the U.S., announced today its participation in a global clinical trial evaluating a treatment for resected high-risk melanoma patients. The Phase 3, randomized V940-001 clinical trial will evaluate Merck and Moderna’s V940 (mRNA-4157), an investigational individualized neoantigen therapy (INT), in combination with KEYTRUDA, Merck’s anti-PD-1 cancer therapy, as a treatment following surgery in patients with resected high-risk (Stage IIB-IV) melanoma. The study will evaluate the safety and efficacy of the INT in combination with KEYTRUDA in this population – as compared to KEYTRUDA alone.

Texas Urology Specialists, part of Texas Oncology, one of the largest community-based oncology practices in the U.S., announced today that the urology care team at USMD is joining the practice, effective March 1. This expansion adds 13 physicians, five advanced practice providers, and more than 45 support staff members to Texas Urology Specialists, along with four locations in the Dallas-Fort Worth metroplex.

Longview, Texas - Texas Oncology, one of the largest community-based oncology practices in the U.S., announced today a major expansion and renovation of its Longview location. The more than $11 million project will add 3,000 square feet of space to the cancer center located at 1300 N. 4th St., increasing the facility’s size by 11% percent.

Carrum Health, a value-based Centers of Excellence healthcare solution changing how we pay for and deliver cancer and surgical care, and Texas Oncology, one of the largest community-based oncology practices in the U.S., today announced a new collaboration to provide high-quality, cost-effective breast cancer care to patients.

Texas Oncology, one of the largest community-based oncology practices in the U.S., and Navigating Cancer, a leading provider of oncology digital healthcare solutions, today announced significant patient benefits from an extensive deployment of routine electronic patient-reported outcomes (ePRO) coupled with systematic patient navigation. Key findings presented at the 2023 ASCO Quality Care Symposium include a significant reduction in patient hospitalizations, a related reduction in overall cost of care, and fewer deaths.
 

BEAUMONT – Texas Oncology, one of the largest community-based oncology practices in the U.S., marked today the recent opening of its new 32,000 square-foot cancer care center, located on the CHRISTUS Southeast Texas St. Elizabeth campus. The new, larger center was built to enable Texas Oncology to provide an enhanced patient experience while meeting the growing need for cancer care in Beaumont and throughout Southeast Texas.

Ranking 6^th in Texas on Forbes ‘America’s Best Employers by State’ list highlights Texas Oncology’s commitment to a quality workforce focused on patient care.

Texas Oncology, one of the largest community-based oncology practices in the U.S., announced today the expansion of its services in the Rio Grande Valley region to include surgical oncology, with the addition of Vijian Dhevan, M.D., MBA, FACS to the physician team. Dr. Dhevan is board-certified in general surgery and has expertise in surgical oncology, as well as bariatric, pediatric (non-oncology procedures), and robotic surgery.

DALLAS – A new bill taking effect on Sept. 1 will expand lifesaving biomarker testing in Texas, helping connect cancer patients with new therapies that are more targeted and effective, especially in cases of advanced disease. Texas Oncology joined with other leading cancer care advocacy groups to encourage passage of Senate Bill 989, which was signed into law on May 30 and requires health insurance companies to cover biomarker testing. Texas is the 11th state to expand access to biomarker testing.